Stephan Kendall, MD
Medical Oncology · Salt Lake City, UTNPI 1033293196
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 258 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,709, 8.8 times the $195 reported in 2019.
Across 258 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$534
- Daiichi Sankyo Inc.$534
- Novartis$468
- Pfizer$427
- Merck$278
- AstraZeneca$253
- plus $2K from 35 others
Across 1,143 payments — averaging $8925.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.3M
- Merck$1.2M
- Pfizer$1.1M
- Incyte Corporation$701K
- Daiichi Sankyo Inc.$631K
- Boehringer Ingelheim$477K
- plus $3.8M from 31 others
What the payments were for
- Food & beverage$4,57293%
- Education$3297%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,901 in reported general payments places this provider in the 60th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 52 | $727,076 |
| IbrancePalbociclib | 30 | $462,609 |
| LenvimaLenvatinib Mesylate | 17 | $459,876 |
| XtandiEnzalutamide | 21 | $265,585 |
| BosulifBosutinib | 13 | $230,715 |
| LonsurfTrifluridine/Tipiracil Hcl | 13 | $209,407 |
| TagrissoOsimertinib Mesylate | 12 | $203,938 |
| Abiraterone Acetate | 19 | $36,143 |
| Hydroxyurea | 75 | $2,107 |
| Anastrozole | 63 | $694 |
| Letrozole | 18 | $496 |
| Prochlorperazine Maleate | 35 | $442 |
| Oxycodone Hcl | 18 | $411 |
| Lorazepam | 27 | $360 |
| Prednisone | 50 | $346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $64 | $727,07652 claims |
| PfizerIbrance, Bosulif | $427 | $693,32543 claims |
| Eisai Inc.Lenvima | $59 | $459,87617 claims |
| Astellas Pharma US IncXtandi | $29 | $265,58521 claims |
| AstraZenecaTagrisso | $253 | $203,93812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 43 medical oncology providers in Utah.
Other medical oncology in Salt Lake City
- Bradley HunterSalt Lake City$263K
- Robert HavardSalt Lake City$57K
- Wallace AkerleySalt Lake City$38K
- Ignacio Garrido-LagunaSalt Lake City$35K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
- Paul ShamiSalt Lake City$28K
- Nitin ChandramouliSalt Lake City$19K
- Kenneth GrossmannSalt Lake City$15K
- Manish KohliSalt Lake City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.